DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1751)

Chronic Obstructive Pulmonary Disease | Landscape & Forecast | Disease Landscape & Forecast

Chronic Obstructive Pulmonary Disease | Landscape & Forecast | Disease Landscape & Forecast

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

MARKET OUTLOOK

The COPD market is continuing its gradual shift away from LABA/ICSFDCs toward LABA/LAMA FDCs, but current and emerging generics will have a significant impact on this trend. Some branded-generic and generic LABA/ICSFDCs have already launched in the United States and Europe, and more will reach the market in the United States in the near future; given that cost remains a significant driver, competition from these generics is expected to impact uptake of both LABA/LAMAs and emerging LABA/LAMA/ICSFDCs. Physicians are eager to have alternative treatments for this chronic disease as development of novel drug classes continues in COPD.

QUESTIONS ANSWERED

  • How will markets react to the launch of generic LABA/ICSFDCs and tiotropium? Will there be significant country-to-country differences in uptake of these generics?
  • Will LABA/LAMAFDCs continue to gain market share, or will generic therapies or branded LABA/LAMA/ICSFDCs threaten these agents?
  • What proportion of patients currently receive a combination of two or more therapies in separate inhalers? How many receive triple therapy, and will these patients be shifted to FDCs?
  • Which emerging therapies have the most potential for uptake? Will nebulized therapies be accepted?

PRODUCT DESCRIPTION

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • COPD Webinar: Impact of Changing Perceptions of ICSs
      • COPD Webinar: Impact of Changing Perceptions of ICSs
      • November 2018
      • August 2018
      • June 2018
    • Market Outlook
      • Key Findings
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Chronic Obstructive Pulmonary Disease?
        • What Factors Are Constraining the Market for Chronic Obstructive Pulmonary Disease?
      • Drug-Class-Specific Trends
        • LAMAs
        • LABA/ICS FDCs
        • LABA/LAMA FDCs
        • LABA/LAMA/ICS FDCs
        • LABAs
        • Nebulized LABAs and LAMAs
        • Nebulized PDE Inhibitors
    • Forecast
    • Etiology and Pathophysiology
      • Etiology and Pathophysiology
        • Disease Overview
      • Etiology
      • Pathophysiology
      • Disease Progression
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Total Prevalent Cases: GOLD Defined or Spirometric Negative
        • Diagnosed Prevalent Cases of COPD
        • Diagnosed Prevalent Cases of COPD by Severity
        • Drug-Treated Cases of COPD
        • Acute Exacerbations of Chronic Obstructive Pulmonary Disease
        • Eosinophilic Chronic Obstructive Pulmonary Disease
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • LAMAs
        • LABAs
        • LABA/ICS FDCs
        • LABA/LAMA FDCs
        • LABA/LAMA/ICS FDCs
        • Oral PDE4 Inhibitors
        • Short-Acting Bronchodilators
        • SABA/SAMA FDCs
        • Methylxanthines
      • Medical Practice
        • Overview
        • Treatment Guidelines
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Chronic Obstructive Pulmonary Disease
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Notable Developments Among Key Emerging Therapies for COPD
        • LAMAs
        • LABA/LAMA/ICS FDCs
        • Nebulized PDE3/4 Inhibitors
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for COPD
      • Key Discontinuations and Failures in COPD
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • COPD Bibliography

Already a Client? Log in to access this report.

  • Pub Date: November 2018
  • Author(s): Emily Schriner, MPH; Stephanie Niquita
  • Emily is an Business Insights Analyst with the Immune and Inflammatory Disorders team at Decision Resources Group. She has authored several content pieces for immune market research reports and keeps the team up-to-date on the immune markets through research on patent life, pricing, and pipeline information. Emily earned her Master of Public Health in Nutrition at West Chester University, focusing on research, analysis, and program development. She completed an internship at Nemours Health Network in Wilmington, Delaware where she did nutrition education development and primary research on program evaluation before initially joining DRG as a data analyst on the Research Analytics Team.

  • Stephanie Niquita works as an associate epidemiologist at Decision Resources Group. Stephanie holds a masters in public health specializing in epidemiology from TISS, Mumbai and a medical degree from Hubei University of Chinese Medicine, People’s Republic of China. She has been trained as a community physician and has also supervised and coordinated various governmental and non-governmental public health projects.

Purchase Report

Recent reports:
You may also be interested in: